Glucose-dependent insulinotropic polypeptide drugs, or GIP-based therapies, are explained: how they work, types, dosing, safety, and what research shows.
Glucose-dependent insulinotropic polypeptide drugs are medications that act on GIP, an incretin hormone released by the small intestine after meals. The only FDA-approved drug in this class today is tirzepatide (Mounjaro, Zepbound), a dual GIP and GLP-1 receptor agonist cleared for type 2 diabetes and chronic weight management. Several other GIP-based compounds, including GIP receptor blockers, remain investigational in the United States.
What GIP Is and Where It Comes From
GIP stands for glucose-dependent insulinotropic polypeptide, though older research papers still call it gastric inhibitory polypeptide. It is a 42-amino-acid hormone produced by K cells in the upper small intestine.
After you eat fat, protein, or carbohydrate, GIP enters the bloodstream and travels to the pancreas, where it amplifies insulin release. An enzyme called DPP-4 breaks GIP down within minutes, which is one reason native GIP works best as a short, meal-triggered signal rather than a long-acting medicine.
The glucose dependent insulinotropic polypeptide mechanism of action begins at the GIP receptor, a class B G-protein-coupled receptor found on pancreatic beta cells, fat cells, bone cells, and in the brain.
How GIP-Based Drugs Work
Pancreas and blood sugar
GIP increases insulin secretion only when blood glucose is already elevated. That glucose dependence is why GIP-based therapies rarely cause low blood sugar on their own.
GIP also influences glucagon release, which surprised early researchers because glucagon raises blood sugar. In a dual GIP/GLP-1 drug, the GLP-1 component helps offset that effect.
Appetite, fat, and other tissues
GIP receptors in the brain and adipose tissue appear to affect satiety and fat storage. Some research suggests that blocking GIP signaling, not activating it, may support weight loss, which is one reason both agonists and antagonists are under study.
- GIP receptor agonists: amplify incretin signaling and are used in dual agonists such as tirzepatide.
- GIP receptor antagonists: block GIP signaling and are usually paired with GLP-1 agonism.
- DPP-4 inhibitors: slow the breakdown of GIP and GLP-1, raising both modestly.
Types of GIP Drugs and Their Approval Status
| Drug or class | Target | FDA status | Main use |
|---|---|---|---|
| Tirzepatide (Mounjaro, Zepbound) | Dual GIP/GLP-1 receptor agonist | Approved | Type 2 diabetes, chronic weight management |
| DPP-4 inhibitors (sitagliptin, linagliptin) | Enzyme inhibitor | Approved | Type 2 diabetes |
| Maridebart cafraglutide (MariTide) | GIP receptor antagonist plus GLP-1 agonist | Investigational | Obesity and type 2 diabetes research |
| Native GIP and GIP analogs | GIP receptor agonist | Not approved as drugs | Laboratory research only |
Tirzepatide is given as a once-weekly subcutaneous injection, typically starting at 2.5 mg and titrated upward under medical supervision. Native GIP is not sold as a prescription drug, and early animal studies using GIP alone showed only weak effects on blood sugar.
No GIP-only medication has been approved by the FDA for human use. Every approved product in this space either combines GIP activity with GLP-1 activity or raises both hormones indirectly.
Peptide Structure and Manufacturing
Because GIP is a peptide, its activity depends entirely on polypeptide structure — the exact order and folding of its 42 amino acids. Change one residue and receptor binding can drop sharply.
Drug developers therefore modify the chain with fatty acid side chains or other stabilizers so the molecule survives longer in the body. These modified compounds belong to the broader insulinotropic polypeptide family of incretin-based therapeutics.
GIP drugs are not antimicrobials. Unlike polypeptide antibiotics such as colistin, which disrupt bacterial membranes, GIP-based medicines act on human hormone receptors.
Supplements, Diet, and Unproven Claims
There is no proven glucose-dependent insulinotropic polypeptide supplement that meaningfully raises GIP levels in humans. Because GIP is a peptide, a swallowed capsule would be digested in the stomach before it could reach the bloodstream intact.
What does raise GIP naturally is food. Meals rich in fat, protein, or refined carbohydrate trigger a larger GIP release than a glass of water or a low-calorie snack.
- No oral GIP pill is FDA-approved for any health condition.
- Products marketed as "GIP boosters" have very little human trial data behind them.
- Diet quality, sleep, and physical activity influence incretin signaling more reliably than any supplement.
Safety, Side Effects, and Monitoring
Tirzepatide carries a boxed warning about thyroid C-cell tumors observed in rodents. It is not recommended for people with a personal or family history of medullary thyroid cancer or MEN2 syndrome.
Common side effects include nausea, vomiting, diarrhea, constipation, and injection-site reactions. These symptoms are usually worst during dose increases and often ease with time.
More serious risks reported with GIP and GLP-1 therapies include pancreatitis, gallbladder disease, and hypoglycemia when combined with insulin or sulfonylureas. All medications in this class are prescription-only, so anyone considering them should discuss benefits, costs, and monitoring with a healthcare professional.
GIP-based drugs remain an active research area. Studies are ongoing in fatty liver disease, heart failure with obesity, sleep apnea, and bone health, but those results are still developing and should not be described as proven benefits.
Frequently Asked Questions
What are glucose-dependent insulinotropic polypeptide drugs used for?
The approved drug in this class, tirzepatide, is used for type 2 diabetes and chronic weight management. DPP-4 inhibitors are also approved for type 2 diabetes and raise GIP indirectly. GIP receptor antagonists are still investigational and are not available by prescription.
Is there a GIP supplement that actually works?
No oral GIP supplement has been proven to raise GIP levels in humans. GIP is a 42-amino-acid peptide, so it would be broken down in the digestive tract if swallowed. Eating a meal with fat, protein, or carbohydrate raises GIP naturally and reliably.
How are GIP drugs different from GLP-1 drugs?
GIP and GLP-1 are both incretin hormones released after eating, but they act differently. GLP-1 slows stomach emptying and suppresses glucagon, while GIP mainly amplifies glucose-dependent insulin release and affects fat tissue. Dual agonists such as tirzepatide target both receptors at once.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.